Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CYDYNASDAQ:NGMOTCMKTS:PKPHNASDAQ:PRLD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYDYCytoDyn$0.35-0.6%$0.31$0.10▼$0.49$441.39M1.293.25 million shs598,653 shsNGMNGM Biopharmaceuticals$1.54$1.55$0.60▼$4.69$128.53M1.271.47 million shsN/APKPHPeak Pharmaceuticals$1.00$2.71$0.52▼$9.12$392K0.549,053 shsN/APRLDPrelude Therapeutics$1.01+4.7%$0.88$0.61▼$6.80$56.74M1.25197,626 shs16,317 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYDYCytoDyn0.00%+0.97%-9.31%+48.80%+163.53%NGMNGM Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%PKPHPeak Pharmaceuticals0.00%0.00%-59.68%-66.67%-52.38%PRLDPrelude Therapeutics0.00%-6.79%+8.71%+27.18%-75.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYDYCytoDyn0.0458 of 5 stars0.02.00.00.00.60.00.0NGMNGM BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APKPHPeak PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APRLDPrelude Therapeutics3.0881 of 5 stars3.22.00.00.02.75.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYDYCytoDyn 0.00N/AN/AN/ANGMNGM Biopharmaceuticals 0.00N/AN/AN/APKPHPeak Pharmaceuticals 0.00N/AN/AN/APRLDPrelude Therapeutics 2.33Hold$4.00298.01% UpsideCurrent Analyst Ratings BreakdownLatest CYDY, PKPH, PRLD, and NGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/29/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$4.00 ➝ $4.004/8/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYDYCytoDyn$270K1,634.77N/AN/A($0.11) per share-3.21NGMNGM Biopharmaceuticals$4.42M29.10N/AN/A$1.80 per share0.86PKPHPeak PharmaceuticalsN/AN/AN/AN/AN/AN/APRLDPrelude Therapeutics$7M8.11N/AN/A$4.32 per share0.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYDYCytoDyn-$49.84M-$0.01N/A∞N/AN/AN/A-76.70%8/14/2025 (Estimated)NGMNGM Biopharmaceuticals-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/APKPHPeak Pharmaceuticals-$160KN/A0.00∞N/AN/AN/A-159.55%N/APRLDPrelude Therapeutics-$121.83M-$1.69N/AN/AN/AN/A-66.89%-55.59%8/11/2025 (Estimated)Latest CYDY, PKPH, PRLD, and NGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025PRLDPrelude Therapeutics-$0.47-$0.42+$0.05-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYDYCytoDynN/AN/AN/AN/AN/ANGMNGM BiopharmaceuticalsN/AN/AN/AN/AN/APKPHPeak PharmaceuticalsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYDYCytoDynN/A0.350.35NGMNGM BiopharmaceuticalsN/A7.797.79PKPHPeak PharmaceuticalsN/A0.150.15PRLDPrelude TherapeuticsN/A7.047.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYDYCytoDyn5.06%NGMNGM Biopharmaceuticals75.74%PKPHPeak PharmaceuticalsN/APRLDPrelude Therapeutics79.72%Insider OwnershipCompanyInsider OwnershipCYDYCytoDyn0.54%NGMNGM Biopharmaceuticals35.90%PKPHPeak Pharmaceuticals18.40%PRLDPrelude Therapeutics63.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYDYCytoDyn201.25 billion1.22 billionNot OptionableNGMNGM Biopharmaceuticals13883.46 million53.50 millionOptionablePKPHPeak Pharmaceuticals1392,000320,000Not OptionablePRLDPrelude Therapeutics12056.46 million20.47 millionOptionableCYDY, PKPH, PRLD, and NGM HeadlinesRecent News About These CompaniesPrelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLCJune 8, 2025 | marketbeat.comPrelude Therapeutics to Present at Major Healthcare Conferences in June 2025June 3, 2025 | msn.comPrelude Therapeutics to Participate in Upcoming Healthcare ConferencesJune 2, 2025 | globenewswire.comPrelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challengesMay 28, 2025 | investing.comPathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drugMay 15, 2025 | fiercebiotech.comPrelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical ProgramsMay 10, 2025 | msn.comPrelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comPrelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025May 5, 2025 | msn.comPrelude Therapeutics to Participate in Citizens Life Sciences ConferenceMay 1, 2025 | globenewswire.comPrelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer TherapiesApril 30, 2025 | msn.comPrelude Announces Presentations at 2025 AACR Annual MeetingApril 25, 2025 | globenewswire.comPrelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should KnowApril 10, 2025 | zacks.comPrelude Therapeutics Founder Acquires 28% More StockMarch 29, 2025 | finance.yahoo.comPrelude Therapeutics CEO buys $467K in common stockMarch 28, 2025 | markets.businessinsider.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in StockMarch 28, 2025 | insidertrades.comPrelude Therapeutics stock surges on insider buyingMarch 27, 2025 | investing.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 SharesMarch 15, 2025 | insidertrades.comPrelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline AdvancementsMarch 14, 2025 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)March 12, 2025 | markets.businessinsider.comBarclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)March 12, 2025 | markets.businessinsider.comPrelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)March 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYDY, PKPH, PRLD, and NGM Company DescriptionsCytoDyn OTCMKTS:CYDY$0.35 0.00 (-0.59%) As of 06/13/2025 03:59 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.NGM Biopharmaceuticals NASDAQ:NGMNGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.Peak Pharmaceuticals OTCMKTS:PKPH$1.00 0.00 (0.00%) As of 06/13/2025Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.Prelude Therapeutics NASDAQ:PRLD$1.00 +0.04 (+4.68%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
